Listen to RFI News
Expand Player
Listen Download Podcast
  • Paris Live PM 1300 - 1400 GMT
    News bulletin 08/21 13h00 GMT
  • Paris Live PM 1300 - 1400 GMT
    News bulletin 08/20 13h00 GMT
  • Paris Live PM 1300 - 1400 GMT
    News bulletin 08/19 13h00 GMT
  • 13h00 - 14h00 GMT
    News bulletin 04/05 13h00 GMT
  • 13h00 - 14h00 GMT
    News bulletin 04/04 13h00 GMT
  • 13h00 - 14h00 GMT
    News bulletin 04/03 13h00 GMT
To take full advantage of multimedia content, you must have the Flash plugin installed in your browser. To connect, you need to enable cookies in your browser settings. For an optimal navigation, the RFI site is compatible with the following browsers: Internet Explorer 8 and above, Firefox 10 and +, Safari 3+, Chrome 17 and + etc.

French drug trial patient dies after being left brain-dead for week

media French Health Minister Marisol Touraine and clinical neurology professor Gilles Hedan at a press conference about the drug trial tragedy Reuters/Stephane Mahe

The man who was left brain-dead after a drugs trial in a French laboratory has died. Five other volunteers remain in hospital in a "stable condition", the hopsital that has been treating them said.

The Rennes university hospital announced the man's death on Sunday.

He had been admitted a week earlier suffering from side-effects incurred during a trial for a pain and mood disorder medication developed by a Portuguese company, Bial, and tested at the Biotrial private laboratory in the western French city.

The five other men who had taken the highest dose of the drug remained in hospital on Sunday.

Three of them were suffering a "handicap that could be irreversible" and another had neurological problems, the neurology department head, Pierre-Gilles Edan, said on Friday.

The other had shown no symptoms but was being monitored.

The 84 other volunteers exposed to the drug have all been contacted and 10 came to the hospital for check-ups but did not show the same "anomalies" as the hospitalised patients, a statement said.

Bial is cooperating with the investigation and vows it followed "international best practice" in developing the drug.

Sorry but the period of time connection to the operation is exceeded.